Business
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study
Johnson & Johnson today announced final overall survival (OS) results from the Asia patients of the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib monotherapy showed amivantamab plus lazertinib led to a clinically meaningful OS improvement in the first-line treatment of Asian patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. Median OS fo
About this update from Johnson & Johnson
[{"type":"text","content":"SINGAPORE, Dec. 8, 2025 First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinib among Asian patients.","length":183,"tagName":"p"},{"type":"text","content":"Median overall survival not yet reached and is projected to exceed four years, which would surpass osimertinib monotherapy by more than one year.","length":150,"tagName":"p"},{"type":"text","content":"/PRNewswire/ -- Johnson & Johnson today announced final overall survival (OS) results from the Asia patients of the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib monotherapy showed amivantamab plus lazertinib led to a clinically meaningful OS improvement in the first-line treatment of Asian patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. Median OS for this chemotherapy-free regimen is projected to exceed four years, which would represent a more than one-year improvement compared to osimertinib alone. These results were presented during a proffered paper session at the European Society for Medical Oncology (ESMO) Asia Congress 2025 (Abstract #972O).[1]","length":857,"tagName":"p"},{"type":"image","alt":"Johnson & Johnson logo (PRNewsfoto/Johnson & Johnson)","displaySize":"","headline":null,"caption":"Johnson & Johnson logo (PRNewsfoto/Johnson & Johnson)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":37,"url":"https://media.zenfs.com/en/prnewswire.com/69c6b64bb2bb88dcb0943d1efbea3054"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rRLmoj5rMO8dbT_3XSwfxg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTY1O2NmPXdlYnA-/https://media.zenfs.com/en/prnewswire.com/69c6b64bb2bb88dcb0943d1efbea3054","width":400,"height":37}},"href":"https://mma.prnewswire.com/media/2771572/1298d71d_502d_4bb1_9019_512d4a14e9a7_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Amivantamab plus lazertinib demonstrated a 26 percent lower risk of death compared to osimertinib monotherapy and is projected to extend survival well beyond what has historically been possible," said presenting author and lead trial investigator Dr. Hidetoshi Hayashi*, M.D., ...